Drug Trial Radar · NCT07951515
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,188
Planned (sponsor's estimate)
Start
Dec 21, 2026
Primary completion
Nov 19, 2029
Study completion Nov 19, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat macular edema after retinal vein occlusion (ME-RVO). ME-RVO happens when a vein becomes blocked in the retina, the back part of the eye. This blockage causes fluid to leak into the macula, which is the part of the retina that helps to see fine details. The buildup of fluid, called macular edema, can cause blurry vision. In this trial, researchers want to learn if a trial medicine called MK-8748 can treat ME-RVO. A standard (usual) treatment for ME-RVO is aflibercept. However, standard treatments such as aflibercept may not work for every person. The main goal of this trial is to learn if participants who receive MK-8748 can see as clearly as participants who receive aflibercept.
Conditions
- Retinal Vein Occlusion
- Macular Edema
Interventions
MK-8748Drug
Administered via intravitreal (IVT) injection
AfliberceptDrug
Administered via IVT injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Best-Corrected Visual Acuity (BCVA) (Early Treatment of Diabetic Retinopathy Study [ETDRS] Letters) From Baseline to Week 24Time frame: Baseline and Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.